Evoke Pharma Inc (NASDAQ:EVOK) Expected to Post Earnings of -$0.12 Per Share

Analysts predict that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.14) per share during the same quarter last year, which would suggest a positive year over year growth rate of 14.3%. The firm is expected to report its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Evoke Pharma will report full-year earnings of ($0.41) per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of ($0.22) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04).

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “hold” rating on shares of Evoke Pharma in a research report on Tuesday, May 28th. Zacks Investment Research lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Finally, B. Riley set a $5.00 price objective on shares of Evoke Pharma and gave the stock a “buy” rating in a research report on Monday, March 4th.

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Evoke Pharma in the 1st quarter valued at about $118,000. Marshall Wace LLP acquired a new position in Evoke Pharma in the 1st quarter valued at about $139,000. Finally, BlackRock Inc. raised its stake in Evoke Pharma by 5.5% in the 4th quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after purchasing an additional 4,392 shares during the last quarter. 7.40% of the stock is owned by hedge funds and other institutional investors.

Evoke Pharma stock opened at $0.56 on Friday. Evoke Pharma has a 52 week low of $0.53 and a 52 week high of $3.40. The stock has a 50-day simple moving average of $0.63.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Recommended Story: What is meant by holder of record?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.